(ShareCast News) - Buy shares in Dunelm Group, said the Sunday Times' Inside the City column. On Wednesday the home furnishings retailer is due to publish its first annual results under new chief executive John Browett. In the final three months of the year the FSTE 250 company - a sort of cut-price John Lewis that should do well if the economy suffers a slowdown post-Brexit - saw like-for-like sales fall 0.6%, not helped by an earlier Easter and a extra week the year before, with total sales up 2.5%. It has a good dividend history.Dunelm's share have not recovered all their losses since the EU referendum vote and CEO Browett also has a shot at redemption with the company. After a premature exit from his roles as Apple's retail chief and a short stint heading Monsoon Accessorise, following a senior role at Tesco and as CEO of Dixons Retail, Browett was brought in by the founding Adderly family to fine-tune the business not for a total overhaul. For Browett, who has looked at managing stock levels and expanding store numbers into London, this will be a big week.Shares in Green REIT are worth holding, according to Questor in the Sunday Telegraph. The real estate investment trust, which has final results due on Monday, is focused on developing office space and industrial parks in Ireland, where the property market is seeing green shoots after a tough few years. What may boost the Irish market further is the opportunity from Brexit, with finance sector companies looking to move to a nearby EU country - and Dublin offers the same language and a supportive tax regime.As well as weak levels of consumer confidence, the Apple tax wrangle remains a major sword above the head of the Ireland's tax haven - though it should not put too many companies off. Green REIT has been improving its debt levels recently by selling off some non-core parts of the portfolio, which has helped the stock outdo the sector benchmark. If Monday's results are positive that should also provide a extra fillip, with some brokers seeing potential for the €1.46 shares to add another 40 cents in the medium-term.Red Pharma is a bargain for the long-term, said Midas in the Mail on Sunday, but be warned - founder chief executive Neil Murray is likely to need to raise further funds before the end of next year. Shares in RedX have sunk to below 27p since they were floated at more than three times that level in March last year. The strategy is to improve existing or close-to-market cancer, infectious diseases and immunology drugs to make them more effective. To be chosen for further development by Redx, drug compounds must have already been tested to some degree, there must be limited competition and the resulting Redx drug must be the best in the market.For example, Murray expects to move into clinical trials late next year on a version of a leukaemia drug that is designed to be more effective for longer than a similar drug produced by Johnson & Johnson and AbbVie. Elsewhere, trials earlier next year are planned for a treatment for pancreatic, breast and head and neck cancers that will target cancer stem cells in these areas of the body - a variation of a treatment first developed by Swiss giant Novartis. There's also a joint venture with the NHS focusing on hospital superbug MRSA and a collaboration with AstraZeneca on certain treatments. There was £14m cash in the bank at last look and the company will be back for more before long. Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only and not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
